Related Experiment Video
Updated: Jun 16, 2025

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Targeting the cholinergic-astrocyte axis: A novel strategy for brain metastasis prevention in lung adenocarcinoma
Xiangze Li1, Kun Liu2, Ziyao Zhang1
1Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Abstract:
Brain metastasis (BM) represents a highly detrimental complication of lung adenocarcinoma (LUAD), persisting even following curative resection of primary tumors, with limited effective preventive measures. This study explores the role of cholinergic metabolism, a pathway crucial for both LUAD progression and brain function, in the pathogenesis of BM. Through comprehensive analysis of RNA-sequencing data from 875 LUAD cases and validation using tissue microarrays from 280 patients, we identified cholinergic metabolic activation as a defining characteristic of tumors prone to BM, which is significantly associated with poor survival outcomes. Mechanistic investigations revealed that acetylcholinesterase (AChE) facilitates BM via dual pro-metastatic mechanisms: immunosuppression and disruption of the blood-brain barrier (BBB). Specifically, AChE-induced overactivation of cholinergic receptors triggers excessive Ca2+ influx, leading to ATP release and astrocyte apoptosis, thereby promoting tumor extravasation across the BBB. Furthermore, choline acetyltransferase enhances tumor aggressiveness by stimulating proliferation and migration. Single-cell RNA sequencing of 26 BM sites and 8 normal brain samples, corroborated by in vitro experiments, elucidated tumor-mediated alterations in the BBB and immune cells. Notably, pharmacological intervention with the AChE inhibitor donepezil exhibited substantial efficacy in preventing BM. Collectively, these findings uncover a targetable cholinergic metabolism-astrocyte axis governing BM organotropism, providing a transformative strategy to intercept metastatic progression in LUAD.
Insights
Lung adenocarcinoma brain metastasis is linked to cholinergic metabolism. Targeting acetylcholinesterase with donepezil shows promise in preventing metastasis and improving survival.
Area of Science:
- Oncology
- Neuroscience
- Metabolism
Background:
- Brain metastasis (BM) is a severe complication of lung adenocarcinoma (LUAD) with poor outcomes.
- Effective preventive strategies for LUAD BM are limited.
- Cholinergic metabolism plays a role in both LUAD progression and brain function.
Purpose of the Study:
- To investigate the role of cholinergic metabolism in the pathogenesis of LUAD brain metastasis.
- To identify potential therapeutic targets for preventing LUAD BM.
Main Methods:
- Analysis of RNA-sequencing data from 875 LUAD cases and validation in 280 patients.
- Mechanistic studies involving acetylcholinesterase (AChE) and choline acetyltransferase.
- Single-cell RNA sequencing of BM samples and in vitro experiments.
- Pharmacological intervention with the AChE inhibitor donepezil.
Main Results:
- Cholinergic metabolic activation is a hallmark of LUAD tumors prone to BM, associated with poor survival.
- AChE promotes BM through immunosuppression and blood-brain barrier (BBB) disruption.
- AChE triggers Ca2+ influx, ATP release, and astrocyte apoptosis, facilitating tumor extravasation.
- Choline acetyltransferase enhances tumor proliferation and migration.
- Donepezil effectively prevented BM in preclinical models.
Conclusions:
- A targetable cholinergic metabolism-astrocyte axis drives LUAD BM organotropism.
- Targeting AChE represents a promising strategy to intercept LUAD metastatic progression.
- Donepezil offers a potential therapeutic approach for preventing BM in LUAD patients.
Related Concept Videos
Alzheimer's Disease: Treatment
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-Acting Cholinergic Agonists: Pharmacokinetics

